Forte highlights that Utertab's intrauterine administration allows it to act directly in the target tissue. It is presented in a perforated blister pack for better sealing.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Given the need to use appropriate first-line antibacterial drugs where possible we are delighted to bring vets a new Tetracycline pessary, ‘Utertab’, for the treatment of metritis and retained foetal membranes.
"In-situ therapy for these conditions has more recently been neglected in favour of injectables but still has much to recommend it. We look forward to highlighting these benefits over the next few months."
For further information on Utertab 2000mg, contact your local Forte Territory Manager or enquiries@fortehealthcare.com.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.